AbbVie’s Contract With Express Scripts Puts Gilead On Defense…And Industry On Notice
Executive Summary
Express Scripts decision to provide AbbVie’s new Viekira Pak as the exclusive treatment option for genotype 1 hepatitis C patients under its national preferred formulary leaves Gilead’s Sovaldi and Harvoni out in the cold and spotlights growing pricing pressure as payers are willing to deny coverage for market-leading drugs.